Clinical trials: Clostridium Difficile Infection
Clostridium Difficile Infection Recurrence
Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection
This is a research study to collect information from people that have Clostridium difficile infection (CDI) and are treated with a standard antibiotic treatment in which the antibiotic dose is gradually reduced over 6 weeks and…
- Trial name
- BEZLO (NCT03880539)
- Testing
- bezlotoxumab, Vancomycin Oral
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Kansas Medical Center
Clostridioides Difficile Infection
Addressing Personalized Needs in Clostridioides Difficile Infection
BEYOND is aiming to demonstrate how by enrichment of the available SPECIFY score, patients at great likelihood for CDI with unfavorable outcome are early detected
- Trial name
- BEYOND (NCT04725123)
- Testing
- Microbiome analysis
- Where
- Greece
- Volunteers
- 153 people
- Sponsor
- Hellenic Institute for the Study of Sepsis
Fecal Microbiota Transplantation, Clostridium Difficile Infection
Fecal Microbiota Transplant National Registry
A national data registry of patients receiving fecal microbiota transplantation (FMT) or other gut-related-microbiota products designed to prospectively assess short and long-term safety and effectiveness
- Conditions
- Fecal Microbiota Transplantation, Clostridium Difficile Infection, Gut Microbiome
- Trial name
- FMT (NCT03325855)
- Testing
- None - Observational
- Where
- 53 sites in United States, Canada
- Volunteers
- 4,000 people
- Sponsor
- American Gastroenterological Association
Enterocolitis Clostridium Difficile Recurrent
FMT Delivered by Capsule Versus Colonoscopy for Recurrent C. Diff
Delivery of FMT by upper route, including gastroscopy, nasogastric/ nasojejunal tube, and lower route, including retention enema, sigmoidoscopy, or colonoscopy have all been utilized successfully.
- Trial name
- NCT02254811
- Testing
- Fecal Microbiota Transplant
- Where
- 2 sites in Canada
- Volunteers
- 116 people
- Sponsor
- University of Alberta
Clostridioides Difficile Infection
Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection
The purpose of this research is to evaluate the primary objectives of safety and efficacy (rate of clinical cure) of 2 dosages of CRS3123 (200 mg and 400 mg) administered orally (po) twice daily (bid) and vancomycin administered…
- Trial name
- NCT04781387
- Testing
- CRS3123, Active Comparator
- Where
- 20 sites in United States, Canada
- Volunteers
- 43 people
- Sponsor
- Crestone, Inc
Clostridium Difficile Infection
Rifaximin for Preventing Relapse of Clostridium Associated Diarrhoea
Clostridium difficile associated diarrhoea is an important cause of morbidity in patients treated with antibiotics, especially in hospital. Clinical relapse occurs after up to 30% of initially successful treatments for colitis.
- Trial name
- RAPID (NCT01670149)
- Testing
- Rifaximin
- Where
- United Kingdom
- Volunteers
- 151 people
- Sponsor
- University of Nottingham
Inflammatory Bowel Diseases, Clostridium Difficile Infection
ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI
This is a randomized controlled trial to assess the clinical and microbiological impacts of FMT in combination with Bezlotoxumab (bezlo) compared to FMT in combination with placebo in patients with both inflammatory bowel disease…
- Trial name
- ICON-2 (NCT03829475)
- Testing
- Bezlotoxumab, Fecal Microbiota Transplantation
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Brigham and Women's Hospital
Recurrent Clostridium Difficile Infection
BIO-K+ CL1285 for Prevention of Recurrent Clostridium Difficile Infection
The primary objective of this study is to evaluate the efficacy of BIO-K+ CL1285 for prevention of recurrent Clostridium difficile infection.
- Trial name
- NCT01202630
- Testing
- Lactobacillus acidophilus CL1285® and Lactobacillus casei
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Bio-K Plus International Inc.
Inflammatory Bowel Diseases, Clostridium Difficile Infection
The ICON Study: Outcomes After FMT for Patients With IBD and CDI
In this study the investigators will evaluate patients with IBD and and at least 2 confirmed c.difficile infections who will be undergoing FMT.
- Trial name
- NCT03106844
- Testing
- Fecal Microbiota Transplantation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Brigham and Women's Hospital
Clostridium Difficile Infection
Freeze-dried, Capsulized FMT for RCDI
Recurrent or refractory Clostridium difficile Infection (RCDI), with a recent increased incidence, is one of the most difficult and increasingly challenges for CDI.
- Trial name
- NCT02399618
- Testing
- Fecal Microbiota Transplantation
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Jinling Hospital, China
Clostridium Difficile Infection
Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection
The purpose of this research is to investigate the efficacy of transplanting screened donor fecal material in treating patients with recurrent Clostridium difficile infection.
- Trial name
- FMT (NCT02326636)
- Testing
- Fecal Microbial Transplantation
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of California, Irvine
Clostridium Difficile
Fecal Transplant for Relapsing C. Difficile Infection
There has been an alarming increase in the incidence and severity of Clostridium difficile infection (CDI) in North America over the past decade.
- Trial name
- NCT01703494
- Testing
- Fecal Microbiota Transplantation
- Where
- 2 sites in United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Colleen Kelly
Clostridium Difficile Infection
Safety and Efficacy of DAV132 in Patients at High-Risk for Clostridium Difficile Infection (CDI)
The purpose of this study is to determine the safe use and evaluate the efficacy/performance of DAV132 in hospitalized patients at high risk for Clostridium difficile infection (CDI) and who receive fluoroquinolones (FQs) for the…
- Trial name
- SHIELD (NCT03710694)
- Testing
- DAV132
- Where
- 29 sites in Bulgaria, Germany and 2 more
- Volunteers
- 260 people
- Sponsor
- Da Volterra
Clostridium Difficile Infection
Seroprevalence of Antibodies to Surface Antigens and Toxins of Clostridioides Difficile
Data on the seroprevalence of antibodies to Clostridioides difficile surface proteins and toxins are scarce. In 1983, Viscidi et al. showed that antibodies to C.
- Trial name
- PREVADIFF (NCT05192148)
- Testing
- Patients
- Where
- 5 sites in France
- Volunteers
- 840 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Recurrent Clostridium Difficile Infection, Multidrug-resistant Klebsiella Pneumoniae Urinary Tract Infection
Fecal Microbiota Transplantation (FMT): PRIM-DJ2727
The Fecal Microbiota Transplantation (FMT) product PRIM-DJ2727 is prepared from human stool from a healthy, screened donor. Requestors will contact the study team about the product (PRIM-DJ2727) by email, visit, or phone call.
- Trial name
- NCT03786900
- Testing
- Fecal Microbiota Transplantation (FMT) product PRIM-DJ2727
- Sponsor
- Herbert DuPont, MD
Infection With AmpC Beta-lactamase Producing Enterobacterales
Clinical Comparison of Treatment Strategies in AmpC Beta-lactamase Producing Enterobacterales in a Swiss Tertiary Care Hospital
This study is to investigate the recent epidemiological trends and the treatment outcome in terms of the length of hospital stay, the relevant renal and neurological side effects, risk factors for developing these side effects…
- Trial name
- AmpCstratBasel (NCT04577989)
- Testing
- data collection
- Where
- Switzerland
- Volunteers
- 270 people
- Sponsor
- University Hospital, Basel, Switzerland
Recurrent C. Difficile Infection
A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4)
This is a Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of the Efficacy, Safety, and Tolerability of a Single Oral Administration of CP101 for the Prevention of Recurrent Clostridioides difficile Infection (PRISM4).
- Trial name
- PRISM4 (NCT05153499)
- Testing
- CP101
- Where
- 68 sites in United States, Canada
- Volunteers
- 19 people
- Sponsor
- Finch Research and Development LLC.
Clostridioides Difficile Infection
Fecal Microbiota Transplantation in Clostridioides Difficile Infection First Episode and First Recurrence
The clinical trial aims to evaluate the efficacy of fecal microbiota transplantation (FMT) after standard of care treatment (either vancomycin or fidaxomicin) vs the pragmatic use of standard of care treatment (either vancomycin…
- Trial name
- FENDER (NCT05266807)
- Testing
- oral capsulized Fecal Microbiota Transplantation, Vancomycin or Fidaxomicin
- Where
- 8 sites in Switzerland
- Volunteers
- 100 people
- Sponsor
- Benoit Guery
Inflammatory Bowel Diseases, Ulcerative Colitis
Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).
The study will compare the effectiveness of Bezlotoxumab in individuals with active C. diff ( Clostridium difficile) infection who are diagnosed with Inflammatory Bowel Disease.
- Conditions
- Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease, C. Diff. Infections
- Trial name
- NCT04626947
- Testing
- Bezlotoxumab
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- David Binion, MD
Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence
Secondary Prevention of Clostridioides Difficile Using Vancomycin
Re-exposure to systemic antibiotics (i.e., antibiotics absorbed into the bloodstream) is common after a Clostridioides difficile infection (CDI) and is the strongest risk factor for a recurrent episode.
- Conditions
- Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, Clostridoides Difficile Associated Disease
- Trial name
- SPORES-V (NCT06979609)
- Testing
- Oral Vancomycin Prophylaxis
- Where
- Canada
- Volunteers
- 300 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre